Expression of type a and b tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc‐AMP and IFN‐γ
- 4 July 1995
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 62 (1) , 76-83
- https://doi.org/10.1002/ijc.2910620115
Abstract
Local administration of high-dose r-TNFα with IFNγ in the limbs of melanoma patients has proved to be a very promising treatment. To understand the role played by the effect of TNF on melanoma cells in tumor destruction, we have investigated the expression of TNF-receptors in melanoma cells using monoclonal antibodies specific for the type-A (75-kDa) and the type-B (55-kDa) TNF receptors. Flow cytometric analysis of cultured melanoma cells indicated the presence of both types of receptor. Quantificative differences in the relative levels of receptors were observed for different cells lines, although the type-B receptor was generally more strongly expressed. Similar results were obtained by immunohistochemistry on cryosections from tumor samples. Positive staining of variable intensity was observed for the type-B TNF-receptor in a high percentage of tumor cells. The type-A TNF-receptor was also detected, but with a weaker staining. The total TNF-binding activity of cultured melanoma cells, as measured by binding of 125l-labeled TNFα, was up-regulated between 2- and 4-fold by incubation of cells with activators of protein kinase A or IFNγ. Treatment of cultured melanoma cells with dbc-AMP resulted in a selective induction of type-A TNF-receptors, without affecting the type-B receptor level. In contrast, IFN-y was able to induce either type of receptor in a cell-line-dependent fashion. Addition of TNFγ to melanoma cells induced the activation of the nuclear transcription factor KB, as measured in an electrophoretic mobility shift assay, thus indicating the biological significance of the TNF-receptors on these cells. © 1995 Wiley-Liss Inc.Keywords
This publication has 26 references indexed in Scilit:
- Bcl‐2 protects from oxidative damage and apoptotic cell death without interfering with activation of NF‐κB by TNFFEBS Letters, 1994
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Two TNF receptorsImmunology Today, 1992
- Cytokine‐mediated modulation of HLA‐class II, ICAM‐1, LFA‐3 and tumor‐associated antigen profile of melanoma cells. comparison with anti‐proliferative activity by RIL1‐β, RTNF‐α, RIFN‐γ, RIl4 and their combinationsInternational Journal of Cancer, 1990
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- Effects of recombinant human tumor necrosis factor-α on the surface phenotype and the growth of human malignant glioma cell linesInternational Journal of Cancer, 1988
- The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.The Journal of Experimental Medicine, 1988
- Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell linesEuropean Journal of Cancer and Clinical Oncology, 1986
- Tumor Necrosis Factor (TNF)Science, 1985
- Monoclonal antibody to a human leukocyte‐specific membrane glycoprotein probably homologous to the leukocyte‐common (L‐C) antigen of the ratEuropean Journal of Immunology, 1980